Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Current practice for the provision of late second trimester abortion (dilation and evacuation, or D&E) often involves the administration of digoxin into the fetal compartment to induce fetal demise prior to the procedure. Digoxin may be administered transabdominally or transvaginally into the fetal compartment. Both modes of administration have been shown in prospective studies to be highly effective and safe. Both modes of administration are considered standard of care. This pilot study will directly compare transabdominal and transvaginal digoxin with respect to patient preference (i.e, patient pain score describing discomfort with injection).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, Los Angeles
• Treatments: Digoxin

Criteria

Inclusion Criteria:

• Age greater than or equal to 18 years

• Singleton viable gestation

• Identifying as primarily English-speaking

• Body mass index less than 40 kilograms/meters squared

• Already a consented patient for second-trimester abortion procedure with digoxin to be performed for termination of pregnancy at the study site

• No medical contraindication to digoxin (i.e., no cardiac dysfunction, no renal dysfunction, no hypersensitivity to digoxin)